Highlights Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 08:56:28 27/06/2024 pm IST			After market 01:26:34 am
2.905 ^EUR	+1.57%		2.918	+0.45%

25/06	ADRs End Higher; Nanobiotix S.A. Climbs 12%	DJ
24/06	Inventiva: boosted by authorization to buy back shares	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inventiva: boosted by authorization to buy back shares	24/06	CF
Inventiva: share price falls, cash flow concerns	22/05	CF
Inventiva: DMC recommends continuation of study	17/05	CF
Inventiva, Inc. Announces Amendments to the Pipeline Programs and Clinical Trials	17/05	CI
Inventiva: additional Phase 2 results in NASH	13/05	CF
Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor	13/05	CI
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	20/03	DJ
Inventiva: positive results from phase 2 clinical trial	19/03	CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin	19/03	CI
Inventiva: NATiV3 study pause lifted	08/03	CF
Inventiva Announces Voluntary Pause on Screening and Randomization of Its NATiV3 clinical trial	08/03	CI
Inventiva: share price falls, phase III recruitment suspended	16/02	CF
Inventiva S.A. Provides Update on its Clinical Trial NATiV3	16/02	CI
Inventiva: second tranche drawn from the EIB	11/01	CF
Inventiva Says First Person Randomized in China in Phase 3 Trial of Lanifibranor for Nonalcoholic Steatohepatitis	21/12	MT
Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program	21/12	CI
Inventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Inventiva Gains 17% on Licensing Deal for Fatty Liver Disease Drug Candidate in Japan, South Korea	21/23/21	MT
Inventiva: licensing agreement with Hepalys Pharma	21/23/21	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inventiva

Equities

IVA

FR0013233012

Highlights

Filters